Objective:

To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the risk of substance use disorders (SUDs) among US veterans with type 2 diabetes, emphasizing the veteran population.

Key Findings:

• GLP-1 RA initiation was associated with a lower risk for the composite endpoint of all incident SUDs (HR, 0.86), translating to about 7 fewer cases per 1,000 patients over 3 years, with modest absolute risk differences for individual SUDs.

Interpretation:

The findings suggest a potential role for GLP-1 receptor agonists in the context of SUDs, but do not support their use specifically for preventing or treating these disorders; they may inform clinical decisions regarding antihyperglycemic therapy.

Limitations:

• The study is observational and subject to possible residual confounding and misclassification, which may affect the reliability of the findings.

Conclusion:

The study indicates that GLP-1 RAs may be relevant in selecting antihyperglycemic therapy for patients with type 2 diabetes at risk for SUDs, but any advantages must be weighed against known adverse effects, emphasizing the need for careful clinical consideration.